<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518698</url>
  </required_header>
  <id_info>
    <org_study_id>18273</org_study_id>
    <nct_id>NCT02518698</nct_id>
  </id_info>
  <brief_title>Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population</brief_title>
  <official_title>Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to provide a detailed description of treatments for CRPC (Castrate
      Resistant Prostate Cancer) patients with bone metastases and the resource utilization and
      costs associated with that diagnosis and subsequent treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2015</start_date>
  <completion_date type="Actual">September 30, 2017</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival of mCRPC patients</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>mCRPC: Metastatic castrate-resistant prostate cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of skeletal related events (SREs) of the mCRPC patients</measure>
    <time_frame>Up to 30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of skeletal related events (SREs) of the mCRPC patients</measure>
    <time_frame>Up to 30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with mCRPC with bone metastases</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of treatments associated with mCRPC</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Treatments could include chemotherapy or bone radiation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration for each treatment identified</measure>
    <time_frame>Up to 30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of providers by treatment</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Distribution of treatments for mCRPC patients will be tracked by the type of provider (oncologist, versus urologist, versus radiation oncologist, etc)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical and demographic characteristics of the mCRPC patients</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Gender, age, geographical region and race/ethnicity, Key comorbidities will also be documented using the Deyo-Charlson Comorbidity Index (DCCI); laboratory results for Prostate-Specific Antigen (PSA) and alkaline phosphatase (ALP) testing using laboratory claims; Rx utilization including opioid use</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment patterns of mCRPC patients with bone metastases</measure>
    <time_frame>Up to 30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression of the disease of mCRPC patients</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause healthcare resource utilization for mCRPC patients</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Using all post-index medical and pharmacy claims, compute the count of physician office visits, outpatient services, inpatient stay, length of inpatient stay, ancillary services, and count of pharmacy claims</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mCRPC-specific healthcare resource utilization for mCRPC patients</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Healthcare resource utilization will be measured using all post-index medical and pharmacy claims to create counts for physician office visits, outpatient services, inpatient stay, length of inpatient stay, ancillary services and counts of pharmacy claims</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause healthcare costs for mCRPC patients</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Healthcare costs will be determined using all post-index medical and pharmacy claims. The all-cause total (medical + pharmacy), medical and pharmacy costs will be computed. A family of general linear model analysis will be performed (medical, pharmacy, and total costs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mCRPC-specific healthcare costs for mCRPC patients</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Healthcare costs will be determined using all post-index medical and pharmacy claims where a diagnosis of mCRPC appears in any of the nine diagnosis positions. The mCRPC specific total (Medical + pharmacy), medical and pharmacy costs associated with these claims will be computed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1163</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 / Treatment patterns</arm_group_label>
    <description>Patients with castrated resistant prostate cancer and bone metastases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223 dichloride (Xofigo, BAY88-8223)</intervention_name>
    <description>Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)</description>
    <arm_group_label>Cohort 1 / Treatment patterns</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Castrated resistant prostate cancer patients with bone metastases
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First diagnosis for bone metastases for members diagnosed with prostate cancer found
             in the claims data during the identification period

          -  Members age ≥ 55 to 89 years at index

          -  Medicare members with medical and pharmacy coverage; and

          -  Continuously enrolled during the pre- and post-index periods.

        Exclusion Criteria:

          -  Member with diagnosis of any other cancer (excluding melanoma (ICD-9 172.x) and other
             metastases (ICD-9 198.x)) before the index date; and

          -  Members age ≥ 89 years of age at index date
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>August 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>September 17, 2018</last_update_submitted>
  <last_update_submitted_qc>September 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Castrated resistant prostate cancer</keyword>
  <keyword>Patients with bone metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

